We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: obesity
MedXY News
EnglishTag

obesity

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

CagriSema: A Breakthrough Combination Therapy for Weight Loss in Adults with Overweight or Obesity
Diabetes & EndocrinologycagrilintideCagriSema

CagriSema: A Breakthrough Combination Therapy for Weight Loss in Adults with Overweight or Obesity

By MedXY|Oct 5, 2025

A phase 3a trial shows coadministered cagrilintide and semaglutide (CagriSema) significantly reduce body weight up to 20.4% over 68 weeks in adults with overweight or obesity, with manageable side effects, offering a promising new option fo

Efficacy and Safety of Ecnoglutide, a cAMP-Biased GLP-1 Receptor Agonist, in Weight Management for Overweight and Obese Adults: Insights from a Phase 3 Multicentre Randomised Trial
Diabetes & Endocrinology
Ecnoglutide
GLP-1 receptor agonist

Efficacy and Safety of Ecnoglutide, a cAMP-Biased GLP-1 Receptor Agonist, in Weight Management for Overweight and Obese Adults: Insights from a Phase 3 Multicentre Randomised Trial

By MedXY|Oct 5, 2025

This review synthesizes evidence from a multicentre, phase 3 trial on ecnoglutide, demonstrating significant and sustained weight loss in overweight/obese adults without diabetes, with a favorable safety profile, supporting its clinical use

Improving Sleep Quality through Cognitive Behavioural Therapy Alters Food Preferences in Adults with Overweight and Obesity
Diabetes & Endocrinologyobesitysleep quality

Improving Sleep Quality through Cognitive Behavioural Therapy Alters Food Preferences in Adults with Overweight and Obesity

By MedXY|Oct 5, 2025

Cognitive behavioural therapy for insomnia enhances self-reported sleep quality and duration, reduces cravings for sweet and savoury foods, and shifts implicit food preferences in adults with overweight or obesity, though dietary intake cha

Untangling Adiposity and Insulin Resistance in HFpEF: Clarifying Their Distinct Impact on Cardiac Function
CardiologyCardiac RemodelingHFpEF

Untangling Adiposity and Insulin Resistance in HFpEF: Clarifying Their Distinct Impact on Cardiac Function

By MedXY|Oct 4, 2025

This study reveals that excess adiposity, rather than insulin resistance or diabetes, predominantly drives left heart abnormalities and elevated pulmonary pressures in HFpEF, highlighting the need for targeted cardiometabolic therapies beyo

Microbiota-Mediated Weight Loss: Insights from the WLM3P Multicomponent Program in Obesity
Diabetes & Endocrinologygut microbiotaobesity

Microbiota-Mediated Weight Loss: Insights from the WLM3P Multicomponent Program in Obesity

By MedXY|Oct 3, 2025

The WLM3P weight loss program significantly remodels gut microbiota, enriching beneficial bacteria such as Faecalibacterium, which associates with improved fat and visceral fat loss in adults with obesity compared to standard low-carb diets

Debunking 7 Common Weight Loss Myths: What You Need to Know for Healthy Fat Loss
Diabetes & Endocrinologyexercisehealthy lifestyle

Debunking 7 Common Weight Loss Myths: What You Need to Know for Healthy Fat Loss

By MedXY|Oct 3, 2025

Explore seven prevalent misconceptions about weight loss—from ignoring obesity as a disease to the dangers of rapid slimming—founded on medical evidence and expert advice to guide safe and effective weight management.

Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial
CardiologyBMICentral Adiposity

Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial

By MedXY|Oct 3, 2025

Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.

Examining the Link Between Obesity and Kidney Outcomes in Heart Failure with Preserved Ejection Fraction
Cardiologyheart failureHFpEF

Examining the Link Between Obesity and Kidney Outcomes in Heart Failure with Preserved Ejection Fraction

By MedXY|Oct 2, 2025

A pooled analysis of four heart failure trials explores the relationship between obesity and kidney outcomes, revealing waist circumference and waist-to-height ratio as key risk factors, while body mass index showed no significant associati

Simvastatin Added to Escitalopram in Obese Patients With Major Depression: A Rigorous RCT Shows No Antidepressant Benefit Despite Improved Cardiometabolic Markers
Cardiologymajor depressionobesity

Simvastatin Added to Escitalopram in Obese Patients With Major Depression: A Rigorous RCT Shows No Antidepressant Benefit Despite Improved Cardiometabolic Markers

By MedXY|Oct 2, 2025

A multicenter double-blind RCT (n=160) found that 12 weeks of simvastatin (40 mg) added to escitalopram did not improve depressive symptoms versus placebo, although LDL, total cholesterol, and CRP were reduced.

Three Weeks of Ketogenic Diet Significantly Boosts Skeletal Muscle Insulin Sensitivity in Obesity: Insights from a Randomized Crossover Trial
Clinical Updatesinsulin sensitivityketogenic diet

Three Weeks of Ketogenic Diet Significantly Boosts Skeletal Muscle Insulin Sensitivity in Obesity: Insights from a Randomized Crossover Trial

By MedXY|Oct 2, 2025

A 3-week ketogenic diet improved skeletal muscle insulin sensitivity and promoted weight loss in individuals with obesity, without significant effects on liver or adipose tissue insulin sensitivity.

Ketogenic vs. Mediterranean Diets in Overweight Hypertensive Patients: Insights from the Keto-Salt Pilot Study
CardiologyHypertensionketogenic diet

Ketogenic vs. Mediterranean Diets in Overweight Hypertensive Patients: Insights from the Keto-Salt Pilot Study

By MedXY|Oct 2, 2025

A head-to-head comparison of ketogenic and Mediterranean diets demonstrates comparable benefits on weight, blood pressure, and metabolic health in overweight hypertensive adults over three months.

Effect of a Ketogenic Diet, Time-Restricted Eating, or Alternate-Day Fasting on Weight Loss in Adults with Obesity: A Randomized Clinical Trial
Cardiologyketogenic dietMediterranean diet

Effect of a Ketogenic Diet, Time-Restricted Eating, or Alternate-Day Fasting on Weight Loss in Adults with Obesity: A Randomized Clinical Trial

By MedXY|Oct 2, 2025

This clinical trial compares the weight loss effects of ketogenic diet, time-restricted eating, and alternate-day fasting against a Mediterranean diet in adults with obesity over three months.

Clinical Advances in Akkermansia muciniphila-Based Interventions: Respiratory Symptom Relief, Muscle Strength Enhancement, and Obesity Management
Clinical UpdatesAkkermansia muciniphilaclinical trial

Clinical Advances in Akkermansia muciniphila-Based Interventions: Respiratory Symptom Relief, Muscle Strength Enhancement, and Obesity Management

By MedXY|Oct 2, 2025

Recent clinical trials reveal the therapeutic potential of Akkermansia muciniphila strains in alleviating respiratory symptoms, improving muscle strength, and preventing diet-induced obesity in dogs.

Personalized Probiotic Therapy: Akkermansia muciniphila Supplementation in Overweight and Obese Type 2 Diabetes—Baseline Levels Matter
Clinical UpdatesAkkermansia muciniphilagut microbiota

Personalized Probiotic Therapy: Akkermansia muciniphila Supplementation in Overweight and Obese Type 2 Diabetes—Baseline Levels Matter

By MedXY|Oct 2, 2025

Akkermansia muciniphila supplementation improves metabolic outcomes in overweight/obese type 2 diabetes patients only when baseline gut levels are low, underscoring the need for personalized microbiota-guided interventions.

How High-Fiber Diets and Supplements Can Improve Health for Patients With Obesity
Family Medicine & Nutritionmetabolic healthnutrition

How High-Fiber Diets and Supplements Can Improve Health for Patients With Obesity

By MedXY|Oct 1, 2025

High-fiber diets and supplements can aid weight management, improve metabolic health, and reduce obesity-related risks by enhancing digestion, promoting satiety, and regulating blood sugar levels.

Semaglutide Shows Promise in Type 1 Diabetes with Obesity: Insights from the ADJUST-T1D Trial
Clinical Updatesclinical trialobesity

Semaglutide Shows Promise in Type 1 Diabetes with Obesity: Insights from the ADJUST-T1D Trial

By MedXY|Oct 1, 2025

Semaglutide significantly improved glycemic control and weight loss in adults with type 1 diabetes and obesity, without increasing major safety risks, according to the ADJUST-T1D trial.

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia
Clinical Updatesclinical trialclozapine

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia

By MedXY|Oct 1, 2025

Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.

Amycretin: A Novel Unimolecular GLP-1 and Amylin Receptor Agonist for Obesity – Early-Phase Clinical Insights and Broader GLP-1 Drug Development Perspective
Clinical Updatesamycretinclinical trial

Amycretin: A Novel Unimolecular GLP-1 and Amylin Receptor Agonist for Obesity – Early-Phase Clinical Insights and Broader GLP-1 Drug Development Perspective

By MedXY|Oct 1, 2025

Amycretin, a new unimolecular GLP-1 and amylin agonist, demonstrated significant weight loss and acceptable tolerability in a phase 1b/2a study, underscoring its potential as an anti-obesity therapy.

Advances in Obesity and Diabetes Management: Highlights from ADA 2025
Diabetes & EndocrinologyAmerican Diabetes Associationcagrilintide

Advances in Obesity and Diabetes Management: Highlights from ADA 2025

By MedXY|Sep 30, 2025

New weight-loss drug combinations, oral semaglutide cardiovascular outcomes, inhaled insulin for type 1 diabetes, and benefits of switching from diet drinks to water were key ADA 2025 findings.

Obesity-Linked Liver Cancer: A Preventable Crisis on the Rise
Medical Newsliver cancerMASLD

Obesity-Linked Liver Cancer: A Preventable Crisis on the Rise

By MedXY|Sep 30, 2025

Over 60% of liver cancer cases are preventable, yet rising obesity and metabolic dysfunction threaten progress. The Lancet Commission outlines urgent strategies to curb a projected doubling of global liver cancer burden by 2050.

Prev
6 / 7
1…4567
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities